JP7373170B2 - ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 - Google Patents

ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 Download PDF

Info

Publication number
JP7373170B2
JP7373170B2 JP2021520287A JP2021520287A JP7373170B2 JP 7373170 B2 JP7373170 B2 JP 7373170B2 JP 2021520287 A JP2021520287 A JP 2021520287A JP 2021520287 A JP2021520287 A JP 2021520287A JP 7373170 B2 JP7373170 B2 JP 7373170B2
Authority
JP
Japan
Prior art keywords
disclosed
compound
compounds
acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021520287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530559A5 (https=
JPWO2019246603A5 (https=
JP2021530559A (ja
Inventor
シー． バード，ジョン
イー． グッドウィン，トーマス
エルガマル，オラ
ハートライン，エリン
アブドゥラヒム，ムアッド
イー． ベネット，チャド
マドフカ ヴィブート，サンディップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hendrix College
Original Assignee
Hendrix College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hendrix College filed Critical Hendrix College
Publication of JP2021530559A publication Critical patent/JP2021530559A/ja
Publication of JP2021530559A5 publication Critical patent/JP2021530559A5/ja
Publication of JPWO2019246603A5 publication Critical patent/JPWO2019246603A5/ja
Application granted granted Critical
Publication of JP7373170B2 publication Critical patent/JP7373170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021520287A 2018-06-22 2019-06-22 ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 Active JP7373170B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688612P 2018-06-22 2018-06-22
US62/688,612 2018-06-22
PCT/US2019/038622 WO2019246603A1 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Publications (4)

Publication Number Publication Date
JP2021530559A JP2021530559A (ja) 2021-11-11
JP2021530559A5 JP2021530559A5 (https=) 2022-06-30
JPWO2019246603A5 JPWO2019246603A5 (https=) 2022-06-30
JP7373170B2 true JP7373170B2 (ja) 2023-11-02

Family

ID=68984309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520287A Active JP7373170B2 (ja) 2018-06-22 2019-06-22 ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物

Country Status (14)

Country Link
US (3) US11312686B2 (https=)
EP (2) EP4438042A3 (https=)
JP (1) JP7373170B2 (https=)
KR (1) KR102821649B1 (https=)
CN (1) CN112672744B (https=)
AU (2) AU2019288813B2 (https=)
BR (1) BR112020026308A2 (https=)
CA (1) CA3103557A1 (https=)
ES (1) ES2994093T3 (https=)
IL (1) IL279586B (https=)
MX (1) MX2021000143A (https=)
SG (1) SG11202012029PA (https=)
WO (1) WO2019246603A1 (https=)
ZA (1) ZA202007620B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
WO2021134045A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
AU2020411507A1 (en) * 2019-12-26 2022-07-14 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase
EP4121050A4 (en) * 2020-03-20 2024-04-17 Clear Creek Bio, Inc. STABLE POLYMORPHOUS COMPOSITIONS OF BREQUINA SODIUM, METHODS OF USE AND PRODUCTION THEREOF
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
WO2023278778A1 (en) * 2021-06-30 2023-01-05 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
CN115896025B (zh) * 2021-08-20 2025-08-26 合肥中科普瑞昇生物医药科技有限公司 人原代急性髓系白血病细胞的培养基及培养方法
US20250009740A1 (en) * 2021-11-22 2025-01-09 Ohio State Innovation Foundation Methods and compositions for targeting alternative metabolism along with flt3 inhibitor-mediated antileukemic actions
CN115532290B (zh) * 2022-10-13 2024-04-30 浙江昌海制药有限公司 一种特定晶面选择性氢化催化剂及其制备方法和应用
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510352A (ja) 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888346A (en) * 1955-08-22 1959-05-26 Gen Aniline & Film Corp Ultra-violet absorbing compounds
AU2896097A (en) * 1996-05-10 1997-12-05 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
HRPK20041072B3 (hr) * 2002-05-17 2007-07-31 Aventis Pharma S.A. Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
EP2948450A4 (en) 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc METALLOENZYMINHIBITORVERBINDUNGEN
HRP20181908T1 (hr) 2013-02-25 2019-01-11 Aurigene Discovery Technologies Limited Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze
US20190192501A1 (en) * 2016-08-23 2019-06-27 Icahn School Of Medicine At Mount Sinai Methods for treating pten-mutant tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510352A (ja) 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物

Also Published As

Publication number Publication date
CN112672744A (zh) 2021-04-16
AU2023233065B2 (en) 2025-09-25
US11999697B2 (en) 2024-06-04
AU2019288813B2 (en) 2023-06-29
IL279586A (en) 2021-01-31
AU2023233065A1 (en) 2023-10-05
KR20210048483A (ko) 2021-05-03
US20240294477A1 (en) 2024-09-05
IL279586B (en) 2021-09-30
US20210253531A1 (en) 2021-08-19
ES2994093T3 (en) 2025-01-17
MX2021000143A (es) 2021-08-05
EP4438042A2 (en) 2024-10-02
EP4438042A3 (en) 2024-12-04
BR112020026308A2 (pt) 2021-03-30
US11312686B2 (en) 2022-04-26
WO2019246603A1 (en) 2019-12-26
SG11202012029PA (en) 2021-01-28
EP3793562A4 (en) 2021-07-07
US20220064119A1 (en) 2022-03-03
CA3103557A1 (en) 2019-12-26
EP3793562A1 (en) 2021-03-24
JP2021530559A (ja) 2021-11-11
CN112672744B (zh) 2022-10-14
AU2019288813A1 (en) 2021-01-07
ZA202007620B (en) 2023-02-22
EP3793562B1 (en) 2024-06-19
KR102821649B1 (ko) 2025-06-17
EP3793562C0 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
JP7373170B2 (ja) ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物
JP7736275B2 (ja) 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
TW202408538A (zh) Stat降解劑及其用途
JP7800865B2 (ja) ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
US20230109418A1 (en) Compositions for use for the inhibition of dihydroorotate dehydrogenase
JP2024525428A (ja) 抗ｃｄ４７－ｓｉｒｐα治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法及び組成物
HK40043086A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
US20230089524A1 (en) Compositions for use in the inhibition of dihydroorotate dehydrogenase
HK40043086B (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
KR102956115B1 (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물
HK40082914A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
HK40084674A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220622

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231013

R150 Certificate of patent or registration of utility model

Ref document number: 7373170

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150